{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T21:06:06Z","timestamp":1648847166665},"reference-count":26,"publisher":"Japan Society for Clinical Immunology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn. J. Clin. Immunol.","Jpn.J.clin.Immun"],"published-print":{"date-parts":[[2014]]},"DOI":"10.2177\/jsci.37.74","type":"journal-article","created":{"date-parts":[[2014,5,15]],"date-time":"2014-05-15T23:08:37Z","timestamp":1400195317000},"page":"74-82","source":"Crossref","is-referenced-by-count":2,"title":["Pathophysiology and new treatment of uveitis"],"prefix":"10.2177","volume":"37","author":[{"given":"Ryoji","family":"YANAI","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Yamaguchi University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsunobu","family":"TAKEDA","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kyusyu Kyushu University Graduate School of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeru","family":"YOSHIMURA","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kyusyu Kyushu University Graduate School of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SONODA","family":"Koh-Hei","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Yamaguchi University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"972","reference":[{"key":"1","unstructured":"1) Foster, C.S., et al.: <i>Diagnosis &amp; treatment of uveitis<\/i> (Jaypee Brothers Medical Publishers Ltd., New Delhi) 2nd Ed., 2013."},{"key":"2","unstructured":"2) Ohguro, N., et al.: The 2009 prospective multi-center epidemiologic survey of uveitis in Japan. <i>Jpn J Ophthalmol<\/i>. <b>56<\/b>: 432-435, 2012."},{"key":"3","unstructured":"3) Goto, H., et al.: Epidemiological survey of intraocular inflammation in Japan. <i>Jpn J Ophthalmol<\/i>. <b>51<\/b>: 41-44, 2007."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Kaburaki, T., et al.: Beh\u00e7et&apos;s disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. <i>Jpn J Ophthalmol<\/i>. 2014. In press.","DOI":"10.1007\/s10384-013-0294-0"},{"key":"5","unstructured":"5) Okada, A.A., et al. and Ocular Behcet&apos;s Disease Research Group Of Japan: Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. <i>Arch Ophthalmol<\/i>. <b>130<\/b>: 592-598, 2012."},{"key":"6","unstructured":"6) Doty, J.D., et al.: Treatment of sarcoidosis with infliximab. <i>Chest<\/i>. <b>127<\/b>: 1064-1071, 2005."},{"key":"7","unstructured":"7) Galor, A., et al.: Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. <i>Ophthalmology<\/i>. <b>113<\/b>: 2317-2323, 2006."},{"key":"8","unstructured":"8) Anink, J., et al.: Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab? <i>Rheumatology<\/i>. <b>52<\/b>: 1674-1679, 2013."},{"key":"9","unstructured":"9) Mushtaq, B., et al.: Adalimumab for sight-threatening uveitis in Behcet&apos;s disease. <i>Eye<\/i>. <b>21<\/b>: 824-825, 2007."},{"key":"10","unstructured":"10) Dobner, B.C., et al.: A three-centre experience with adalimumab for the treatment of non-infectious uveitis. <i>Br J Ophthalmol<\/i>. <b>97<\/b>: 134-138, 2013."},{"key":"11","unstructured":"11) Suhler, E.B., et al.: Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. <i>Br J Ophthalmol<\/i>. <b>97<\/b>: 481-486, 2013."},{"key":"12","unstructured":"12) Muranski, P., et al.: Essentials of Th17 cell commitment and plasticity. <i>Blood<\/i>. <b>121<\/b>: 2402-2414, 2013."},{"key":"13","unstructured":"13) Afkarian, M., et al.: T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells. <i>Nat immunol<\/i>. <b>3<\/b>: 549-557, 2002."},{"key":"14","unstructured":"14) Szabo, S.J., et al.: A novel transcription factor, T-bet, directs Th1 lineage commitment. <i>Cell<\/i>. <b>100<\/b>: 655-669, 2000."},{"key":"15","unstructured":"15) Oestreich, K.J., et al.: Transcriptional mechanisms that regulate T helper 1 cell differentiation. <i>Current opinion in immunology<\/i>. <b>24<\/b>: 191-195, 2012."},{"key":"16","unstructured":"16) Yoshimura, T., et al.: Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. <i>Rheumatology<\/i>. <b>48<\/b>: 347-354, 2009."},{"key":"17","unstructured":"17) Hohki, S., et al.: Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. <i>Exp Eye Res<\/i>. <b>91<\/b>: 162-170, 2010."},{"key":"18","unstructured":"18) Haruta, H., et al.: Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. <i>nvest Ophthalmol Vis Sci<\/i>. <b>52<\/b>: 3264-3271, 2011."},{"key":"19","unstructured":"19) Muselier, A., et al.: Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. <i>Ocul Immunol Inflamm<\/i>. <b>19<\/b>: 382-383, 2011."},{"key":"20","unstructured":"20) Hirano, T., et al.: A case of Behcet&apos;s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. <i>Mod Rheumatol<\/i>. <b>22<\/b>: 298-302, 2012."},{"key":"21","unstructured":"21) Adan, A., et al.: Tocilizumab treatment for refractory uveitis-related cystoid macular edema. <i>Graefes Arch Clin Exp Ophthalmol<\/i>. <b>251<\/b>: 2627-2632, 2013."},{"key":"22","unstructured":"22) Adan, A., et al.: Tocilizumab treatment for recalcitrant uveitic macular edema. <i>Graefes Arch Clin Exp Ophthalmol<\/i>. <b>251<\/b>: 2249-2250, 2013."},{"key":"23","unstructured":"23) Genovese, M.C., et al.: LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. <i>Arthritis Rheum<\/i>. <b>62<\/b>: 929-939, 2010."},{"key":"24","unstructured":"24) Papp, K.A., et al.: Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. <i>N Engl J Med<\/i>. <b>366<\/b>: 1181-1189, 2012."},{"key":"25","unstructured":"25) Hueber, W., et al.: Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. <i>Sci Transl Med<\/i>. <b>2<\/b>: 52ra72, 2010."},{"key":"26","unstructured":"26) Baerveldt, E.M., et al.: Successful long-term triple disease control by ustekinumab in a patient with Behcet&apos;s disease, psoriasis and hidradenitis suppurativa. <i>Ann Rheum Dis<\/i>. <b>72<\/b>: 626-627, 2013."}],"container-title":["Japanese Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/37\/2\/37_74\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T04:56:41Z","timestamp":1621486601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/37\/2\/37_74\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2177\/jsci.37.74","relation":{},"ISSN":["0911-4300","1349-7413"],"issn-type":[{"value":"0911-4300","type":"print"},{"value":"1349-7413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}